- Mr. Clean gives Times Square a post-party scrub-down
- Update: P&G officially unveils smartphone-enabled toothbrush
- CVS Caremark to stop selling tobacco in all store locations
- Actavis to pare down sales staff of branded-drugs division
- Walgreens expanding scope of retail pharmacy experience and services heading into fiscal 2014
DUBLIN Quarterly revenue for Warner Chilcott during the third quarter primarily was driven by the company's acquisition of two drugs from Procter & Gamble.
The drug maker said its revenue for the quarter, ended Sept. 30, jumped 178.2% to $703.2 million over the prior-year quarter thanks to its acquisition of Actonel and Asacol. In total, these products and the other new products acquired from P&G contributed $504.4 million in revenue during the quarter, Warner Chilcott said.
Despite its revenue gain, the company reported that its third-quarter profit decreased to $57.5 million, or 23 cents per share, from $424.2 million, or $1.69 per share in the same period last year.
Looking ahead, the drug maker raised its outlook from a range of $3.25 to $3.35 per share to $3.35 to $3.45 per share, although it cut its revenue forecast to a range of $2.8 billion to $2.85 billion, down from its original projection of $2.9 billion to $2.95 billion.